Granulocyte colony-stimulating factor is one of 327 small molecule programs targeting Acute Myeloid Leukemia. It is currently in Phase 3.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
282 competitors in Multiple Myeloma
Empliciti
Venclexta
Keytruda
Sarclisa
Opdivo
BLENREP
Platinol
Mezigdomide
Granulocyte colony-stimulating factor
Cevostamab
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Early-Stage Breast Cancer
NCT05753618
Biliary Atresia
NCT06708572
Poor Graft Function
NCT05669079
Poor Graft Function
NCT05907499
Malignancy
NCT03674411
Neuroblastoma
NCT02605421
Clinical
Sources